Peacock Karen 4

What Happened

• Karen Peacock, a director of IDEXX Laboratories (IDXX), had 101 restricted stock units (RSUs) vest and convert into 101 shares on May 7, 2026. The filing shows the shares were acquired at $0.00 (typical for vested RSUs) and there is no reported sale of the shares.

Key Details

• Transaction date: May 7, 2026. Transaction code: M (exercise/conversion of derivative).
• Shares acquired: 101 common shares at $0.00 per share (conversion of RSUs). A corresponding derivative conversion line is also reported; no cash proceeds or open‑market sale is shown.
• Footnote F1: Each RSU represented a contingent right to one share and vested in one installment on May 7, 2026. Footnote F2: Not applicable.
• Filing date: May 11, 2026. This filing was submitted within the standard 2 business‑day Form 4 deadline for a May 7 transaction.
• Shares owned after the transaction: not specified in the provided filing.

Context

• This was a vesting/settlement of RSUs, not a purchase or a sale. Such vested awards are common compensation events and do not by themselves indicate an insider buying or selling shares for investment reasons. Derivative code M here reflects the conversion/settlement of the award into common stock.